Back to Journals » Therapeutics and Clinical Risk Management » Volume 5

The pathophysiology of paroxysmal nocturnal hemoglobinuria and treatment with eculizumab

Authors Kelly R, Richards S, Hillmen P, Hill A

Published 18 November 2009 Volume 2009:5 Pages 911—921

DOI https://doi.org/10.2147/TCRM.S3334

Review by Single anonymous peer review

Peer reviewer comments 3



Richard Kelly1, Stephen Richards1, Peter Hillmen1, Anita Hill2

1Institute of Oncology, St. James’s University Hospital, Leeds, UK; 2Department of Haematology, Bradford Teaching Hospitals NHS Foundation Trust, Bradford, UK

Abstract: Paroxysmal nocturnal hemoglobinuria is a rare disorder of hemopoietic stem cells. Affected individuals have a triad of clinical associations – intravascular hemolysis, an increased risk of thromboembolism, and bone marrow failure. Most of the symptoms experienced in this disease occur due to the absence of complement regulatory proteins on the surface of the red blood cells. Complement activation is thus not checked and causes destruction of these cells. Eculizumab is a monoclonal antibody treatment which specifically binds to the complement protein C5, preventing its cleavage, and so halts the complement cascade and prevents the formation of the terminal complement proteins. Eculizumab prevents intravascular hemolysis, stabilizes hemoglobin levels, reduces or stops the need for blood transfusions, and improves fatigue and patient quality of life as well as reducing pulmonary hypertension, decreasing the risk of thrombosis and protecting against worsening renal function. It is not a curative therapy but has a great benefit on those with this rare debilitating condition.

Keywords: eculizumab, paroxysmal nocturnal hemoglobinuria, hemolysis

Creative Commons License © 2009 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.